Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Eli Lilly and Company (LLY)

144.75   -0.15 (-0.1%) 11-27 00:36
Open: 144.9 Pre. Close: 144.9
High: 145.34 Low: 142.61
Volume: 2,999,831 Market Cap: 138,465M
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 145.554 - 146.287 146.287 - 146.891
Low: 140.913 - 141.69 141.69 - 142.329
Close: 143.602 - 144.83 144.83 - 145.84

Technical analysis

as of: 2020-11-25 4:41:11 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 177.51     One year: 207.33
Support: Support1: 137.91    Support2: 129.21
Resistance: Resistance1: 151.98    Resistance2: 177.51
Pivot: 143.28
Moving Average: MA(5): 144.39     MA(20): 141.17
MA(100): 149.70     MA(250): 145.78
MACD: MACD(12,26): 0.28     Signal(9): -0.38
Stochastic oscillator: %K(14,3): 58.70     %D(3): 61.90
RSI: RSI(14): 53.23
52-week: High: 170.75  Low: 115.92  Change(%): 23.3
Average Vol(K): 3-Month: 411342  10-Days: 367471

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
LLY has closed below upper band by 31.0%. Bollinger Bands are 43.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to LLY's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Tue, 24 Nov 2020
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer - Yahoo Finance

Tue, 24 Nov 2020
Should Value Investors Choose Eli Lilly and Co (LLY) Stock? - Yahoo Finance

Mon, 23 Nov 2020
why Eli Lilly and Company [LLY] is a Good Choice for Investors After New Price Target of $165.88 - The DBT News

Fri, 20 Nov 2020
Eli Lilly and Company (LLY) Presents Tirzepatide SURPASS Program Overview Conference (Transcript) - Seeking Alpha

Wed, 18 Nov 2020
Eli Lilly and Company (LLY) Presents at Wolfe Research Virtual Healthcare Conference (Transcript) - Seeking Alpha

Wed, 18 Nov 2020
Covid-19 Treatment Approval To Drive Eli Lilly Stock Higher? - Forbes

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 957
Shares Float (M) 744
% Held by Insiders 0.16
% Held by Institutions 79.43
Shares Short (K) 4,890
Shares Short P. Month (K) 3,770

Stock Financials

EPS 6.110
EPS Est This Year 4.200
EPS Est Next Year 4.630
Book Value (p.s.) 5.320
Profit Margin 24.01
Operating Margin 27.76
Return on Assets (ttm) 9.8
Return on Equity (ttm) 131.8
Qtrly Rev. Growth 4.8
Gross Profit (p.s.) 18.399
Sales Per Share 24.264
EBITDA (p.s.) 8.091
Qtrly Earnings Growth -3.60
Operating Cash Flow (M) 6,650
Levered Free Cash Flow (M) 4,440

Stock Valuations

PE Ratio 23.69
PEG Ratio 1.11
Price to Book value 27.21
Price to Sales 5.97
Price to Cash Flow 20.82

Stock Dividends

Dividend 2.870
Forward Dividend 2.960
Dividend Yield 0.02
Dividend Pay Date 2020-12-09
Ex-Dividend Date 2020-11-11
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.